Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Exclusion Criteria

• •Receiving concomitant cytotoxic or other antineoplastic treatment. Hormone replacement therapy is allowed, as are steroid antiemetics
• •Clinical evidence of central nervous system metastases
• •Active infection
• •Cannot adequately be followed up for the duration of the study
• •A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
• •Use of any investigational agent in the 3 weeks prior to inclusion
• •Serious concomitant systematic disorders incompatible with the study
• •Received more than one previous chemotherapy regimen or had prior gemcitabine treatment
• •Patients with tumor of borderline malignancy
• •Patients with estimated GFR ≤ 50 mL/min